Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05383274 · ClinicalTrials.gov registry record · Phase 4
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
A Phase 4 study of Urethral Stricture, sponsored by Urotronic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 9
- Study locations
NCT05383274: Recruiting Phase 4 study of Urethral Stricture, sponsored by Urotronic.
NCT05383274 is a Phase 4 study of Urethral Stricture that is actively recruiting participants, run by Urotronic. The registered enrollment target is 34 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05383274, a Phase 4 study of Urethral Stricture, is actively recruiting participants, sponsored by Urotronic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 9
- Study locations
Study Summary
Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
Primary Outcome
Average Change in Sperm Concentration from baseline to 3-months
Conditions Studied
Interventions
- COMBINATION_PRODUCT Optilume Urethral DCB
Study Locations (9)
Florida
- Orlando Health - Orlando
- Florida Urology - Tampa
Arkansas
- Arkansas Urology - Little Rock
Louisiana
- Regional Urology - Shreveport
Maryland
- Chesapeake - Hanover
Nevada
- Freedman Urology - Las Vegas
New Jersey
- New Jersey Urolgy - Millburn
New York
- Western New York - Cheektowaga
Texas
- Urology Clinics of North Texas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 4 |
What NCT05383274 shows while recruiting
NCT05383274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Urethral Stricture appearing as the primary indexed condition, and to 1 intervention - of which Optilume Urethral DCB is the first listed.
NCT05383274 lists 9 locations in 8 states (Florida, Arkansas, Louisiana).
Frequently Asked Questions
What is clinical trial NCT05383274 about?
NCT05383274 is a clinical study titled "Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters". Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
What is the current status of trial NCT05383274?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2022-02-14. Estimated completion is 2026-12-30.
What conditions does trial NCT05383274 study?
This clinical trial studies the following conditions: Urethral Stricture.
What interventions are being tested in trial NCT05383274?
The interventions under investigation include: Optilume Urethral DCB (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05383274?
This trial is sponsored by Urotronic, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05383274 being conducted?
This trial has 9 study locations across Arkansas, Florida, Louisiana, Maryland, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urethral Stricture
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05383274's enrollment target sits among peer trials
34 1520th of 2000 higher than 474 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI